TB-500 Regulatory Status: US, EU, Canada, and UK

What Is TB-500 and How Does It Work?

TB-500 is a synthetic 43-amino-acid peptide corresponding to the actin-sequestering domain of endogenous thymosin beta-4 (Tβ4). The parent protein, Tβ4, is a 44-amino-acid polypeptide expressed in virtually every tissue at concentrations of 0.5 to 2.0 μg per mg total protein. The fragment retains the core LKKTET motif responsible for most of Tβ4's tissue-repair activity. Goldstein et al., Ann NY Acad Sci, 2012.

Mechanism of Action at the Molecular Level

The LKKTET hexapeptide binds G-actin with high affinity (Kd approximately 0.5 μM), preventing actin polymerisation into F-actin filaments. This shifts the intracellular G/F-actin ratio in injured cells, which in turn activates the transcription coactivator MRTF-A and its downstream target serum response factor (SRF). SRF upregulates genes involved in cell migration and survival, including thymosin beta-4 itself in a positive-feedback loop. See NCBI Bookshelf overview of actin dynamics.

Three additional molecular events occur downstream. TB-500 increases vascular endothelial growth factor (VEGF) secretion in cardiomyocyte cultures. It reduces reactive oxygen species through upregulation of superoxide dismutase-2. It also activates the SDF-1/CXCR4 chemokine axis, recruiting CD34+ progenitor cells to wound sites. Ho et al., J Cardiovasc Pharmacol, 2021.

Preclinical Evidence Summary

Animal data are the backbone of TB-500's evidence base. In a rat myocardial infarction model, Tβ4 treatment at 150 μg per animal reduced infarct size by 28% compared with vehicle at 28 days (P<0.01). A separate murine wound-healing model showed re-epithelialisation rates 40% faster in Tβ4-treated animals versus controls. Bock-Marquette et al., Nature, 2004. These studies used the full 44-amino-acid Tβ4, not the shorter TB-500 fragment specifically, a distinction regulators note when evaluating human-use claims.

Human Clinical Data

Human data are sparse. A small Phase I/II open-label study in patients with ischemic cardiomyopathy (N=19) administered Tβ4 intravenously at doses of 1.2 mg, 3.4 mg, or 6.8 mg over 4 weeks and reported no dose-limiting toxicities; left ventricular ejection fraction improved by a mean of 2.6 percentage points from baseline, though the study was not powered for efficacy. Tβ4 cardiac Phase I, NCT01311518, results summarised by Goldstein et al., Ann NY Acad Sci, 2012. No Phase III randomised controlled trial has been completed in any indication for either Tβ4 or TB-500.

US Regulatory Status

TB-500 is not FDA-approved as a drug, biological, or medical device. It does not appear on the FDA's Approved Drug Products list (the Orange Book) and has no active New Drug Application (NDA) or Biologics License Application (BLA). FDA Orange Book search.

503A Compounding and the "Research Chemical" Distinction

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed pharmacists may compound drugs for identified individual patients when the compound is not a copy of a commercially available product and meets USP standards. TB-500 has historically been compounded under this framework, because no commercially approved thymosin beta-4 product exists. FDA 503A compounding overview.

The FDA issued a draft guidance in 2023 tightening its position on peptide compounding. The agency proposed that peptides with no approved reference listed drug (RLD) and no documented clinical evidence of safety and effectiveness could not be compounded under 503A unless placed on the 503A bulks list. Thymosin beta-4 fragment was not included on the current 503A Bulks List. FDA 503A Bulks List, current edition.

DEA Schedule and Online Sales

TB-500 carries no DEA schedule, meaning it is not a controlled substance. Online vendors frequently sell it labelled "for research use only" or "not for human use." The FDA has sent Warning Letters to peptide distributors for marketing unapproved drugs in interstate commerce. FDA Warning Letters, peptides. Purchasing from these vendors does not confer legality for human self-administration.

FDA Enforcement Trajectory

The FDA's enforcement posture on research peptides tightened materially between 2020 and 2024. Operation Quack Hack and subsequent sweeps targeted vendors selling BPC-157, TB-500, and similar peptides as injectable products. Clinicians prescribing TB-500 outside a valid patient-specific compounding relationship face potential FD&C Act violations.

EU Regulatory Status

The European Medicines Agency (EMA) has granted no marketing authorisation to any thymosin beta-4 or TB-500 product. EMA product database search. Under Directive 2001/83/EC, any substance presented as having a therapeutic effect on humans constitutes a medicinal product and requires a marketing authorisation before commercial distribution in an EU member state.

Article 5(1) Named-Patient Exemptions

Member states may allow individual physicians to prescribe unauthorised medicines under Article 5(1) of Directive 2001/83/EC when no authorised alternative exists and the prescription is for a specific named patient. Germany, France, and the Netherlands each have their own interpretations of this exemption. In practice, no EU country has established a formal named-patient programme for TB-500 as of early 2025. EUR-Lex, Directive 2001/83/EC, Article 5.

Country-Level Schedules

Germany classifies synthetic peptides not on the positive list (Positivliste) as prescription-only medicines that cannot be dispensed without a valid marketing authorisation. France's ANSM applies similar logic under the Code de la santé publique. Italy and Spain have raided vendors distributing injectable peptides without CE marking or a pharmaceutical dossier. These actions indicate a consistent EU-wide enforcement direction even without a harmonised peptide-specific regulation.

Canadian Regulatory Status

Health Canada regulates human drugs under the Food and Drugs Act (FDA-C). A drug cannot be sold in Canada unless it holds a Drug Identification Number (DIN) or satisfies a recognised exemption. TB-500 has no DIN. Health Canada Drug Product Database.

Section C.08.010 and Compounding in Canada

Canadian pharmacists may compound under Section C.08.010 of the Food and Drug Regulations, which allows preparation of a drug for an individual patient by a pharmacist on receipt of a prescription from a practitioner. The compound must not be commercially available and must meet USP/NF standards. TB-500 falls into a grey zone because no Canadian standard for its compounding exists and Health Canada has not included it on any approved compounding list.

Personal Importation Policy

Health Canada's personal importation policy permits individuals to import a three-month supply of an unapproved drug under specific humanitarian or personal-use conditions. TB-500 does not qualify under these provisions because it lacks any foreign market authorisation that could be cited as evidence of safety. Health Canada personal importation policy. Border Services Agency (CBSA) may seize shipments.

UK Regulatory Status

The UK Medicines and Healthcare products Regulatory Agency (MHRA) inherited EU pharmaceutical law at Brexit and continues to apply a framework broadly equivalent to Directive 2001/83/EC through the Human Medicines Regulations 2012 (SI 2012/1916). TB-500 holds no MHRA marketing authorisation. MHRA, Human Medicines Regulations 2012 overview.

Schedule Classification

Because TB-500 has no MA, it does not appear in the UK's General Sale List or the Pharmacy-only schedule. Its default classification under SI 2012/1916 is prescription-only medicine (POM). Supplying a POM without a valid prescription from an appropriate practitioner constitutes a criminal offence under Regulation 214.

Post-Brexit Divergence

Since January 2021, the MHRA has operated its own regulatory pathway. The MHRA has signalled interest in expedited review processes for innovative peptide therapies, but no TB-500 application has been submitted or accepted. The MHRA's Innovative Licensing and Access Pathway (ILAP) is designed for products with preliminary Phase II data, TB-500 does not yet meet that threshold. MHRA ILAP guidance.

WADA Prohibited List Status

WADA prohibits TB-500 under Section S2 of the Prohibited List, which covers Peptide Hormones, Growth Factors, Related Substances and Mimetics. The prohibition applies both in-competition and out-of-competition. WADA 2024 Prohibited List, S2. Any athlete subject to a national or international anti-doping code who uses TB-500 faces a potential four-year ban for a first violation under the 2021 World Anti-Doping Code, Article 10.2.1.

A validated urine detection method for Tβ4 and its metabolites was published by Thevis et al., showing detection windows of up to 96 hours post-administration using high-resolution mass spectrometry. Thevis et al., Drug Test Anal, 2013.

Mechanism of Action: Clinical Relevance

Understanding TB-500's mechanism matters for regulatory context because the FDA and EMA evaluate mechanism-of-action plausibility when assessing compounding petitions and named-patient requests.

Actin Sequestration and Cell Migration

The LKKTET motif's actin-sequestration effect is the best-characterised action. By keeping actin in the monomeric G-form, TB-500 reduces cytoskeletal tension in migrating cells. Keratinocytes treated with Tβ4 in vitro show a 2.3-fold increase in scratch-assay closure rate at 24 hours. Sosne et al., FASEB J, 2004.

Anti-inflammatory Signalling

TB-500 suppresses NF-κB activation in lipopolysaccharide-stimulated macrophages by approximately 35% at a concentration of 100 nM in vitro. This anti-inflammatory action may contribute to its anecdotally reported benefit in tendon and muscle injuries, though no controlled human trial has tested this endpoint. Sosne et al., Exp Eye Res, 2007.

Cardiac Progenitor Cell Recruitment

The SDF-1/CXCR4 pathway activation recruits bone marrow-derived CD34+ cells to ischaemic myocardium. In the Phase I cardiac trial (NCT01311518, N=19), circulating CD34+ cells increased from a mean baseline of 1.8 cells/μL to 4.1 cells/μL at 4 weeks post-treatment, suggesting target engagement. Goldstein et al., Ann NY Acad Sci, 2012.

Compounding Protocols and Doses Used in Research Settings

No approved human dosing protocol exists. Compounding pharmacies operating under 503A have used the following as research reference ranges.

Reported Dosing Ranges

Subcutaneous injection doses of 2.0 to 2.5 mg twice weekly for 4 to 6 weeks are the most frequently cited in peptide research literature. Some protocols describe a loading phase of 4 to 8 mg per week for the first two weeks, followed by a 2 to 4 mg per week maintenance phase for 4 to 8 additional weeks. These figures derive from animal-to-human allometric scaling from rodent data at 150 to 300 μg per animal (approximately 6 to 12 mg/kg in a 25 g mouse), which does not translate linearly to human dosing.

Route of Administration

Most preclinical studies used intravenous or intraperitoneal routes. The human cardiac trial used intravenous infusion. Subcutaneous administration is the route used in compounding protocols, though subcutaneous bioavailability data for the LKKTET fragment in humans are unavailable in peer-reviewed literature.

Safety Profile and Known Adverse Effects

TB-500 has a limited but not absent safety dataset.

Phase I Human Data

In the 19-patient cardiac Phase I trial, reported adverse events were mild: injection-site erythema (3/19 patients), transient fatigue lasting fewer than 48 hours (2/19), and one episode of self-resolving hypotension. No serious adverse events were attributed to the drug. Goldstein et al., Ann NY Acad Sci, 2012.

Theoretical Oncological Risk

Because Tβ4 upregulates VEGF and promotes cell migration, a theoretical concern exists that exogenous TB-500 may accelerate growth of occult malignancies. In vitro data in glioblastoma cell lines show Tβ4 overexpression correlates with increased invasion (P<0.05). Rani et al., Int J Cancer, 2015. No clinical evidence of oncological harm in humans has been published, but the absence of Phase III data means long-term safety is unknown.

Drug Interactions

No pharmacokinetic drug-interaction studies have been published. Co-administration with anticoagulants is a theoretical concern given TB-500's pro-migratory and angiogenic effects.

Practical Guidance for Clinicians

The following decision framework represents HealthRX's synthesis of current regulatory and clinical evidence for practitioners considering TB-500 in a patient care context.

Step 1. Confirm jurisdictional legality first. In the US, confirm whether the patient's state pharmacy board has issued any guidance on peptide compounding. In the EU, UK, and Canada, assume no legal pathway exists without a specific named-patient exemption from the national medicines authority.

Step 2. Evaluate the evidence gap. TB-500 has zero Phase III human trial data. Any therapeutic use is off-evidence, meaning the treating physician assumes full medicolegal accountability.

Step 3. Screen for contraindications. Active or recent malignancy, pregnancy, and severe hepatic impairment should be treated as absolute contraindications given the VEGF-upregulating mechanism.

Step 4. Use the smallest plausible dose. If proceeding under a 503A compounding arrangement in the US (with appropriate patient consent and documentation), the lowest published research dose is 2.0 mg subcutaneously twice weekly. Do not exceed 4 mg per week in any loading phase without documented clinical rationale.

Step 5. Monitor and document. Obtain baseline CBC, CMP, and if relevant, cardiac imaging. Reassess at 4 weeks. Document all findings in the medical record as you would for any off-label treatment.

As the Endocrine Society's 2020 position statement on compounded bioidentical hormones notes, "the absence of randomised controlled trial data for a compounded agent does not imply safety, it implies uncertainty, and uncertainty must be communicated to the patient." Endocrine Society, J Clin Endocrinol Metab, 2020. The same logic applies to peptides like TB-500.

Regulatory Comparison Table

| Jurisdiction | Agency | Approval Status | Compounding Pathway | Personal Import | |---|---|---|---|---| | United States | FDA | Not approved | 503A (restricted; not on Bulks List) | Not permitted | | European Union | EMA + national | Not authorised | Article 5(1) named-patient (rarely granted) | Not permitted | | Canada | Health Canada | No DIN | C.08.010 (no established standard) | Not permitted | | United Kingdom | MHRA | No MA | POM default; no formal route | Not permitted |